Clinical Trial Detail

NCT ID NCT03383575
Title Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Azacitidine + Enasidenib

Enasidenib

Age Groups: adult senior child

Additional content available in CKB BOOST